Innate Pharma SA (NAS:IPHA)
$ 1.9 0.05 (2.7%) Market Cap: 153.81 Mil Enterprise Value: 93.89 Mil PE Ratio: 0 PB Ratio: 4.75 GF Score: 56/100

Q3 2022 Innate Pharma SA Earnings Call Transcript

Nov 14, 2022 / 01:00PM GMT
Release Date Price: $2.48 (+8.30%)
Operator

Hello, and thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Innate Pharma Publication of Revenue for Third Quarter 2022 Conference Call. (Operator Instructions) I would now like to turn the conference over to Henry Wheeler, Head of Investor Relations. Please go ahead.

Henry Wheeler
Innate Pharma S.A. - VP & Head of IR

Thank you. Good morning, good afternoon, and welcome, everyone. This morning, Innate issued a press release providing a business update for our Q3 '22 results. We look forward to highlighting the progress made during the quarter as well as addressing future goals and milestones. The press release and today's presentation are both available on the IR section of the website. On Slide 2, before we start, I'd like to remind you that we will make forward-looking statements regarding the financial outlook in addition to regulatory and product plan developments. These statements are subject to risks and uncertainties that may cause actual results to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot